Purchase this article with an account.
Clara Battista, Sandro Nardoni, Paola Slanisca, Andrea Romani; Combined Therapy For Subretinal Neovascularzation Secondary To Idiopatic Macular Teleangectasia Type 2. Invest. Ophthalmol. Vis. Sci. 2011;52(14):4527.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the results of the combination therapy with intravitreal bevacizumab and photodynamic therapy (PDT) in a retrospective interventional case series of 10 treatment-naive eyes affected by subretinal neovascularization (SRNV) secondary to idiopatic macular teleangectasia type 2 (MT2).
All patients underwent a best corrected visual acuity (BCVA) measurement by ETDRS chart, FAG, high speed ICG with stereo images before and after treatment. Intravitreal bevacizumab (1mg/0.04ml) was injected and followed within 10 days by PDT. The antiangiogenic therapy was repeated if useful, associated with PDT only if necessary.
Mean follow-up time was 23 months (range from 12 to 35). Mean BCVA at baseline was 20/50 (range from 20/25 to 20/125) and increased at last visit to 20/40 (range from 20/20 to 20/200). All eyes showed stabilization or improvement in BCVA except one and absence of leakage on FAG. Mean PDT number was 1.3 and mean intravitreal injection number was 2.6.
Combination therapy appears logical because of the different and complementary active mechanisms of bevacizumab and PDT that may be efficacious in the treatment of SRNV secondary to MT2.
This PDF is available to Subscribers Only